Cargando…

Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy

BACKGROUND: Platelet to Lymphocyte ratio (PLR) is thought to be associated with a worse outcome in multiple types of cancer. However, the prognostic significance of PLR has not been investigated in the prostate cancer (PCa) patients receiving hormonal therapy. The objective of this study was to dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yanqing, Xu, Fan, Pan, Jiahua, Zhu, Yinjie, Shao, Xiaoguang, Sha, Jianjun, Wang, Zezhou, Cai, Yong, Liu, Qiang, Dong, Baijun, Xue, Wei, Huang, Yiran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879724/
https://www.ncbi.nlm.nih.gov/pubmed/27222030
http://dx.doi.org/10.1186/s12885-016-2363-5
_version_ 1782433713267671040
author Wang, Yanqing
Xu, Fan
Pan, Jiahua
Zhu, Yinjie
Shao, Xiaoguang
Sha, Jianjun
Wang, Zezhou
Cai, Yong
Liu, Qiang
Dong, Baijun
Xue, Wei
Huang, Yiran
author_facet Wang, Yanqing
Xu, Fan
Pan, Jiahua
Zhu, Yinjie
Shao, Xiaoguang
Sha, Jianjun
Wang, Zezhou
Cai, Yong
Liu, Qiang
Dong, Baijun
Xue, Wei
Huang, Yiran
author_sort Wang, Yanqing
collection PubMed
description BACKGROUND: Platelet to Lymphocyte ratio (PLR) is thought to be associated with a worse outcome in multiple types of cancer. However, the prognostic significance of PLR has not been investigated in the prostate cancer (PCa) patients receiving hormonal therapy. The objective of this study was to determine the prognostic value of PLR in PCa patients treated with androgen deprivation therapy (ADT). METHODS: Two-hundred-ninety prostate cancer patients who had undergone ADT as first-line therapy were retrospectively analyzed. The blood cell counts were performed at the time of diagnosis. PLR was calculated as the ratio of platelet count to lymphocyte count. Patients were categorized in two groups using a cut-off point of 117.58 as calculated by the receiver-operating curve analysis. Correlations between PLR and clinical characteristics were analyzed. Meanwhile, univariate and multivariate cox regression analyses were performed to determine the associations of PLR with progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS). Prognostic accuracy was evaluated with the Harrell concordance index. RESULTS: The differences of age, serum prostate-specific antigen (PSA) level, Gleason score, risk stratification and incidence of metastasis between low PLR group (<117.58) and high PLR group (≥117.58) were not statistically significant (p > 0.05). Multivariate analyses identified PLR as an independent prognostic factor for PFS (hazard ratio (HR) = 1.581, p = 0.013), CSS (HR = 1.768, p = 0.037) and OS (HR = 1.650, p = 0.044). The addition of PLR to the final model improved predictive accuracy (c-index: 0.747, 0.801 and 0.768) for PFS, CSS and OS compared with the clinicopathological base model (c-index: 0.730, 0.778 and 0.746), which included Gleason score and incidence of metastasis. CONCLUSIONS: PLR might play a significant role in the prognosis of PCa patients treated with ADT. Thus, we recommend adding PLR to traditional prognostic model to improve the predictive accuracy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2363-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4879724
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48797242016-05-26 Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy Wang, Yanqing Xu, Fan Pan, Jiahua Zhu, Yinjie Shao, Xiaoguang Sha, Jianjun Wang, Zezhou Cai, Yong Liu, Qiang Dong, Baijun Xue, Wei Huang, Yiran BMC Cancer Research Article BACKGROUND: Platelet to Lymphocyte ratio (PLR) is thought to be associated with a worse outcome in multiple types of cancer. However, the prognostic significance of PLR has not been investigated in the prostate cancer (PCa) patients receiving hormonal therapy. The objective of this study was to determine the prognostic value of PLR in PCa patients treated with androgen deprivation therapy (ADT). METHODS: Two-hundred-ninety prostate cancer patients who had undergone ADT as first-line therapy were retrospectively analyzed. The blood cell counts were performed at the time of diagnosis. PLR was calculated as the ratio of platelet count to lymphocyte count. Patients were categorized in two groups using a cut-off point of 117.58 as calculated by the receiver-operating curve analysis. Correlations between PLR and clinical characteristics were analyzed. Meanwhile, univariate and multivariate cox regression analyses were performed to determine the associations of PLR with progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS). Prognostic accuracy was evaluated with the Harrell concordance index. RESULTS: The differences of age, serum prostate-specific antigen (PSA) level, Gleason score, risk stratification and incidence of metastasis between low PLR group (<117.58) and high PLR group (≥117.58) were not statistically significant (p > 0.05). Multivariate analyses identified PLR as an independent prognostic factor for PFS (hazard ratio (HR) = 1.581, p = 0.013), CSS (HR = 1.768, p = 0.037) and OS (HR = 1.650, p = 0.044). The addition of PLR to the final model improved predictive accuracy (c-index: 0.747, 0.801 and 0.768) for PFS, CSS and OS compared with the clinicopathological base model (c-index: 0.730, 0.778 and 0.746), which included Gleason score and incidence of metastasis. CONCLUSIONS: PLR might play a significant role in the prognosis of PCa patients treated with ADT. Thus, we recommend adding PLR to traditional prognostic model to improve the predictive accuracy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2363-5) contains supplementary material, which is available to authorized users. BioMed Central 2016-05-24 /pmc/articles/PMC4879724/ /pubmed/27222030 http://dx.doi.org/10.1186/s12885-016-2363-5 Text en © Wang et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wang, Yanqing
Xu, Fan
Pan, Jiahua
Zhu, Yinjie
Shao, Xiaoguang
Sha, Jianjun
Wang, Zezhou
Cai, Yong
Liu, Qiang
Dong, Baijun
Xue, Wei
Huang, Yiran
Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
title Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
title_full Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
title_fullStr Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
title_full_unstemmed Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
title_short Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
title_sort platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879724/
https://www.ncbi.nlm.nih.gov/pubmed/27222030
http://dx.doi.org/10.1186/s12885-016-2363-5
work_keys_str_mv AT wangyanqing platelettolymphocyteratioasanindependentprognosticindicatorforprostatecancerpatientsreceivingandrogendeprivationtherapy
AT xufan platelettolymphocyteratioasanindependentprognosticindicatorforprostatecancerpatientsreceivingandrogendeprivationtherapy
AT panjiahua platelettolymphocyteratioasanindependentprognosticindicatorforprostatecancerpatientsreceivingandrogendeprivationtherapy
AT zhuyinjie platelettolymphocyteratioasanindependentprognosticindicatorforprostatecancerpatientsreceivingandrogendeprivationtherapy
AT shaoxiaoguang platelettolymphocyteratioasanindependentprognosticindicatorforprostatecancerpatientsreceivingandrogendeprivationtherapy
AT shajianjun platelettolymphocyteratioasanindependentprognosticindicatorforprostatecancerpatientsreceivingandrogendeprivationtherapy
AT wangzezhou platelettolymphocyteratioasanindependentprognosticindicatorforprostatecancerpatientsreceivingandrogendeprivationtherapy
AT caiyong platelettolymphocyteratioasanindependentprognosticindicatorforprostatecancerpatientsreceivingandrogendeprivationtherapy
AT liuqiang platelettolymphocyteratioasanindependentprognosticindicatorforprostatecancerpatientsreceivingandrogendeprivationtherapy
AT dongbaijun platelettolymphocyteratioasanindependentprognosticindicatorforprostatecancerpatientsreceivingandrogendeprivationtherapy
AT xuewei platelettolymphocyteratioasanindependentprognosticindicatorforprostatecancerpatientsreceivingandrogendeprivationtherapy
AT huangyiran platelettolymphocyteratioasanindependentprognosticindicatorforprostatecancerpatientsreceivingandrogendeprivationtherapy